Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MS, Helen Won, MS, Eunhee Kim, PhD, Alan Saven, MD, Martha Wadleigh, MD, Richard M. Stone, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Mario E Lacouture, MD, Neal Rosen, MD PhD, Michael Berger, PhD, Ross L Levine, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 24.

https://doi.org/10.1182/blood.V124.21.24.24

Published: 2014

Journal Articles

Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing

Benjamin Durham, MD, Jing Ma, PhD, Eunhee Kim, PhD, John K. Choi, MD, Patrick Campbell, MD PhD, Juvianee Estrada-Veras, MD, Michael P Walsh, PhD, Mario E Lacouture, MD, Young Rock Chung, MS, Joy Nakitandwe, PhD, Eli Diamond, David M. Hyman, MD, Raajit K. Rampal, MD PhD, Minal Patel, Christopher Y. Park, MD PhD, Tanja A. Gruber, MD PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 1887.

https://doi.org/10.1182/blood.V124.21.1887.1887

Published: 2014

Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 2876.

https://doi.org/10.1182/blood.V122.21.2876.2876

Published: 2013

Journal Articles

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Justin M Watts, MD, Ashwin Kishtagari, MBBS [Co-first author], Sean Devlin, PhD, Eytan M Stein, MD, Jae H Park, MD, Mario E Lacouture, MD, Martin Tallman, MD

Blood (2013) 122 (21): 5274.

https://doi.org/10.1182/blood.V122.21.5274.5274

Published: 2013

Journal Articles

Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis

Emily C Case, Shenhong Wu, MD, PhD, John Gerecitano, MD, PhD, Mario E Lacouture, MD

Blood (2011) 118 (21): 5120.

https://doi.org/10.1182/blood.V118.21.5120.5120

Published: 2011

NARROW

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only